Effects of Naringin on expression of COX-2 mRNA and protein in Human ovarian cancer cell line SKOV3

Abstract

Abstract: AIM: To investigate effects of naringin on expression of COX-2 mRNA and protein of Human ovarian cancer cell line SKOV3.METHODS: SKOV3 cells were cultured in vitro and divided into five groups randomly, namely control group, naringin group (10 μmol/L), naringin group (20 μmol/L), naringin group (40 μmol/L) and celecoxib group (80 μmol/L). The inhibition effects of naringin on cell- proliferation were determined by MTT method. The expression of COX-2 mRNA and protein were evaluated by Western Blot and Real-time quantitative PCR after forty-eight hours.RESULTS: Naringin could inhibit the growth of SKOV3 cells, and with the increase of the dosage and time, the tumor growth inhibition rate increased significantly (P<0.01).Compared with control group,the expression of COX-2 mRNA was down-regulated significantly by every dosage of naringin and celecoxib (0.828±0.006, 0.753±0.011, 0.412±0.216, 0.321±0.017). Meanwhile, the expression of COX-2 protein was down-regulated significantly by every dosage of naringin and celecoxib (1.7925±0.088, 1.2225±0.0822, 1.2725±0.07632, 0.3075±0.0977).CONCLUSION: The appropriate dosage of naringin can inhibit SKOV3 cells growth in vitro, and can down-regulate the expression of COX-2 mRNA and protein.

Key words: Naringin, COX-2, Human Ovarian cancer cell line SKOV3

CLC Number:

R965.2

SONG Shu-hui, HU Xin, XIONG Yu-qing, CAI Li-ping. Effects of Naringin on expression of COX-2 mRNA and protein in Human ovarian cancer cell line SKOV3[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 271-275.

References

[1] 李巍,崔恒. 卵巢癌诊断的研究进展[J]. 中华妇产科杂志, 2005, 40(7): 410-413.
[2] Clever H. A the crossroads of inflammation and cancer[J]. Cell, 2004, 118(6): 671-674.
[3] Menter DG, Schilsky R, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward[J].Clin Cancer Res, 2010, 16(5): 1384-1390.
[4] 生秀杰,房超. 塞来昔布对子宫内膜癌细胞增生和COX-2 mRNA表达的影响[J]. 肿瘤研究与临床, 2007, 19(3): 148-150.
[5] 贾冬英,姚开,谭敏,等. 柚果皮中生理活性成分研究进展[J]. 食品与发酵工业, 2001, 27(11): 74-78.
[6] SalmahY, Hasanah MG, Gan SK. Naringin content in local citrus fruits[J]. Food Chemistry, 1990, 37(2): 113-121.
[7] 黄凤香, 林家逊. 柚皮苷药物动力学及生物活性研究新进展[J]. 华夏医学, 2009, 22(4): 777-779. 　
[8] 苏玲, 刘启德. 柚皮苷生物活性和药代动力学研究新进展[J]. 创新与管理, 2008, 2(1): 74-80.
[9] 熊莺, 王广发, 张俊艳, 等. 柚皮苷抑制高糖诱导的脐静脉内皮细胞与单核细胞的黏附作用[J].南方医科大学学报, 2010, 30(2): 321-325.
[10] Camargo CA, Gomes-Marcondes MC, Wutzki NC, et al. Naringin inhibits tumor growth and reduces interleukin-6 and tumor necrosis factor α levels in rats with Walker 256 carcinosarcoma[J]. Anticancer Res, 2012, 32(1):129-133.
[11] Kawaguchi K. Suppression of lipopolysaccharideinduced tumor necrosis factor-release and liver injury in mice by naringin[J].Eur J Pharmacol,1999, 368(2/3): 245-250.
[12] Menczer J. Cox-2 expression in ovarian malignancies: a review of the clinical aspects[J]. Eur J Obstet Gynecol Repord Biol, 2009, 146(2): 129-132.
[13] Manchana T, Triratanachat S, Sirisabya N, et al. Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer[J]. Gynecol Oncol, 2006, 100(3): 556-560.
[14] Chun KS, Kim SH, Song YS, et al. Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin[J]. Carcinogenesis, 2004,25(5): 713-722.
[15] Park SW, Kim HS, Hah JW, et al. Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines[J]. Anticancer Drugs, 2010, 21(9): 823-830.
[16] Woo JG, Park SY, Lim JC, et al. Acid-induced COX-2 expression and prostaglandin E2 production via activation of ERK1/2 and p38 MAPK in cultured feline esophageal smooth muscle cells[J]. Arch Pharm Res, 2011, 34(12): 2131-2140.
[17] Yamamoto S, Yamane M, Yoshida O, et al. Activations of mitogen-activated protein kinases and regulation of their downstream molecules after rat lung transplantation from donors after cardiac death[J]. Transplant Proc, 2011,43(10): 3628-3633.